Quantcast

Januvia Lawsuit News: Panel to Hear Oral Arguments Later This Month Regarding Consolidation of all Federal Incretin Mimetic Lawsuits, Bernstein Liebhard LLP Reports

July 8, 2013

The Firm is currently investigating Januvia pancreatic cancer lawsuits, as well as Januvia pancreatitis and Januvia thyroid cancer product liability claims.

New York, New York (PRWEB) July 08, 2013

Januvia lawsuit claims filed on behalf of patients who allegedly developed pancreatic cancer, pancreatitis, or thyroid cancer due to their use of the type 2 diabetes drug continue to mount in courts throughout the country, Bernstein Liebhard LLP reports. According to court documents, at least 53 incretin mimetic claims, including Januvia lawsuits, have been filed in federal courts throughout the U.S. The U.S. Judicial Panel on Multidistrict Litigation will meet on July 25th to consider transferring these cases to a multidistrict litigation in a single federal court for pretrial proceedings. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

“Our Firm is receiving Januvia lawsuit inquiries on a regular basis from patients concerned that the drug may have caused them to develop pancreatic cancer, pancreatitis or thyroid cancer. We anticipate that a growing number of claims will be filed over this issue, and agree that a consolidated litigation would allow the lawsuits to proceed efficiently through the courts,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Januvia side effects.

Januvia Lawsuits

According to Bernstein Liebhard LLP, multidistrict litigations are established when a large number of lawsuits are expected to be filed that will involve similar factual litigations. All of the federal claims involving incretin mimetics, including Januvia lawsuits, allege the manufacturers of these drugs failed to provide adequate warnings regarding their alleged association with an increased risk of pancreatic cancer, pancreatitis and thyroid cancer. Consolidation in a single federal jurisdiction would conserve the resources of the court and the parties, and avoid duplicative discovery and inconsistent court rulings.

Januvia and other incretin mimetics reduce blood sugar by stimulating insulin production by the pancreas. In 2009, a caution regarding a potential link between Januvia and pancreatitis was added to the drug’s label after the U.S. Food & Drug Administration (FDA) became aware of 88 post-marketing cases of acute pancreatitis in patients taking Januvia.* Just this past April, the Institute for Safe Medicine Practices published an analysis of the FDA adverse even database which revealed that during the 12 month period ending in June 2012, the agency had received reports of 177 possible cases of pancreatitis,18 cases of pancreatic cancer, and a single case of thyroid cancer in Januvia patients. According to the ISMP, the analysis revealed that, as a class, incretin mimetics were 25 times more likely to be linked to pancreatic cancer compared to other diabetes drugs.**

The FDA announced in March that it was investigating Januvia and other incretin mimetics after results from an unpublished study indicated these medications might cause pre-cancerous changes in the cells of the pancreas.*** Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.****

Patients who have allegedly developed a pancreatic cancer, thyroid cancer or pancreatitis due to Januvia may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more about filing a Januvia lawsuit, please visit Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htmSeptember 25, 2009

**ismp.org/QuarterWatch/pdfs/2012Q3.pdf

***fda.gov/Drugs/DrugSafety/ucm343187.htm, FDA March 2013

****bmj.com/open-data/incretin#alternate; BMJ, June 10, 20

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.januvialawsuit2013.com/

For the original version on PRWeb visit: http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb10907230.htm


Source: prweb



comments powered by Disqus